The hemodialysis and peritoneal dialysis market size is projected to reach $130.37 billion by 2028 from $89.85 billion in 2022; it is expected to grow at a CAGR of 6.4% from 2022 to 2028.
New York, May 27, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Hemodialysis and Peritoneal Dialysis Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Hemodialysis and Peritoneal Dialysis), Product (Devices, Consumables, and Services), and End User (Hospital-Based and Home-Based)”, the global hemodialysis and peritoneal dialysis market growth is driven by the rising prevalence of kidney diseases and increasing incidence of diabetes, the market strategies by key players for development of products. However, risks and complications associated with dialysis hamper the market growth. The hemodialysis segment dominated and held the largest revenue share of 86.09% in 2022. The services segment dominated and held the largest revenue share of 60.98% in 2022. The hospital-based segment dominated and held the largest revenue share of 84.16% in 2022.
The Sample Pages Showcases Content Structure and Nature of Information Included in This Research Study Which Presents A Qualitative and Quantitative Analysis: https://www.theinsightpartners.com/sample/TIPHE100001128/
No. of Charts & Figures
Type, Product, and End User
North America; Europe; Asia Pacific; Latin America; MEA
US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Hemodialysis and Peritoneal Dialysis Market: Competitive Landscape and Key Developments Fresenius Medical Care AG & Co KGaA; DaVita Inc.; Baxter International Inc.; B. Braun Melsungen AG; Diaverum; Nipro Medical Corporation; Evoqua Water Technologies LLC. (Mar Cor Purification); Asahi Kasei Medical Co., Ltd.; Rockwell Medical, Inc.; and Dialife SA are among the leading companies in the hemodialysis and peritoneal dialysis market. The market is anticipated to flourish with the development of innovative products in the coming years.
Schedule A Pre-Sale Discussion with The Author Team in A Slot That You Prefer to Address Queries on Scope of The Study, Customization, Introduction to Research Methodology, Assistance on Technologies and Market Definitions: https://www.theinsightpartners.com/inquiry/TIPHE100001128/
In April 2022, Fresenius Medical Care AG & Co KGaA received 510(k) clearance from the US Food and Drug Administration (FDA) for Versi PD Cycler System. VersiPD is simple, quiet, portable, and advanced device designed to improve health equity by making home therapy a feasible option for a broader population of dialysis patients. The company further announced that the limited rollout of VersiPD began in April 2022. However, wider availability is planned in 2023 and beyond.
In January 2022, B. Braun Melsungen AG announced official ground-breaking of a state-of-the-art Hemodialysis Concentrate Factory in the Thanh Oai Industrial Complex in Hanoi, Vietnam. The company announced the Hemodialysis Concentrate Factory, which has a construction footprint of around 4,000m2 and an initial investment of US$ 5 million that enables B. Braun Vietnam to serve the local and international markets with more than 2.5 million units of 10-litre canisters of hemodialysis concentrate per year. Furthermore, it has helped to create capabilities and jobs for over 160 employees.
North America held the largest share of the hemodialysis and peritoneal dialysis market. The US accounts for the largest share of the regional market, followed by Canada and Mexico. The hemodialysis and peritoneal dialysis market in the US is expected to grow rapidly with growing cases of kidney diseases and favorable government regulations encouraging the development of dialysis procedures for this condition. The National Kidney Foundation report states that ~6,00,000 patients in the US suffer from end-stage kidney disease, among which ~4,60,000 are receiving dialysis annually. The National Institute of Health report reveals that adjusted mortality decreased by ~20% in patients receiving peritoneal dialysis between 2009 and 2018.
Click Here to Avail Lucrative DISCOUNTS on Our Latest Research Reports. We Offer Student, Enterprise, and Special Periodic Discounts to Our Clientele. Please Fill the Form to Know DISCOUNTED PRICE
Moreover, peritoneal dialysis has been strongly recommended in patients seeking urgent states of dialysis in the United States. It is a safe and effective home modality with several advantages over hemodialysis procedures. For example, during an emergency, the peritoneal dialysis procedure is fast compared to the traditional two weeks duration of treatment. Moreover, urgent-start peritoneal dialysis has been shown to have a low incidence of complications such as peritonitis, leaks, catheter malfunction, hospitalizations, and modality failure. However, hemodialysis is commonly followed in large and medium-sized hospitals. The same segment is expected to hold the largest share in North America during the forecast period.
The Canadian Institute for Health Information (CIHI) report states that the number of Canadians receiving chronic (long-term) dialysis (such as hemodialysis) has nearly doubled over 20 years, from 11,601 in 2000 to 23,125 in 2019. The High Risk and High Cost: Focus on Opportunities to Reduce Hospitalizations of Dialysis Patients in Canada by the Canadian Institute for Health Information (CIHI) states that there were ~36,251 Canadians outside Quebec living with ESRD in 2015, and 21,214 of these patients were on dialysis during the same period. The number of kidney transplants does not match the rising demand for kidney transplantation as it is not a cure. Therefore, the number of patients on dialysis has increased by 30% from 2017, as per the Canadian Medical Association Journal report. According to the Canadian Medical Association (CMA) report, every year, about 3,000 patients start long-term dialysis therapy in Canada, a number that is steadily increasing from 0.5% to 1.0% annually. Also, home dialysis modalities, such as peritoneal dialysis, are available mostly in Canadian centers.
Mortality rates associated with peritoneal dialysis are comparable to those associated with in-center hemodialysis, and peritoneal dialysis offers several other advantages, such as improvement in quality of life, higher satisfaction of patient, maintenance of independence, and ability to travel and improve hemodynamic stability. Further, across Canada, the use of peritoneal dialysis varies considerably according to the treating facility and the geographic location. Peritoneal dialysis in Canada has gained huge significance and attention as it provides satisfactory medical outcomes and attempts to minimize regional and facility-related variation, as well as the dialysis type seems reasonable. Such aforementioned factors are responsible for the growth of the overall hemodialysis and peritoneal dialysis market in Canada.
Have A 15-Minute-Long Discussion with The Lead Research Analyst and Author of The Report in A Time Slot Decided by You. You Will Be Briefed About the Contents of The Report and Queries Regarding the Scope of The Document Will Be Addressed as Well: https://www.theinsightpartners.com/speak-to-analyst/TIPHE100001128
Rising Prevalence of Diabetes Fuels Market Growth: Diabetes occurs when blood glucose, also called blood sugar, is too high. High blood glucose can cause health problems over time. The main types of diabetes are type 1, type 2, and gestational. According to International Diabetes Federation, in 2021, approximately 537 million adults (aged 29–70) worldwide were living with diabetes. Further, the total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045. According to the CDC, in 2020, more than 34 million Americans had diabetes, which is nearly 11% of the US population.
According to the American Diabetes Association [ADA], approximately 1.5 million new cases of diabetes are registered every year. According to the World Health Organization, there are about 60 million people with diabetes in Europe and about 10.3% of men and 9.6% of women aged 25 years and over suffer from diabetes. Further, diabetes is more common among older people. Approximately 19.3 million people aged 60–79 have diabetes across European countries, compared to 11.3 million people aged 40–59 and only 1.7 million aged 20–39.
With diabetes, the small blood vessels in the body are injured. When the blood vessels in the kidneys are injured, the kidneys cannot clean the blood properly. The body will retain more water and salt than it should, resulting in weight gain and ankle swelling. Also, waste materials will build up in the blood. Diabetes may also cause damage to nerves in the body, which can cause difficulty in emptying the bladder. The pressure resulting from a full bladder can back up and injure the kidneys. According to a study, about 30% of patients with Type 1 (juvenile-onset) diabetes and 10–40% of those with Type 2 (adult-onset) diabetes will eventually suffer from kidney failure. Therefore, an increase in the prevalence of diabetes also increases the chances of dialysis for a patient's survival, thereby fueling the market growth.
Immediate Delivery of Our Off-The-Shelf Reports and Latest Research Studies, Through Flexible and Convenient Payment Methods: https://www.theinsightpartners.com/buy/TIPHE100001128/
Hemodialysis and Peritoneal Dialysis Market: Segmental Overview
Type-Based Insights: The hemodialysis and peritoneal dialysis market, by type, is bifurcated into hemodialysis and peritoneal dialysis. The hemodialysis segment held a larger share in 2022 and is expected to register a higher CAGR in the market from 2022 to 2028.
Product-Based Insights: The hemodialysis and peritoneal dialysis market, based on product, is segmented into devices, consumables, and services. In 2022, the services segment held the largest share of the market. However, the consumables segment is expected to register the highest CAGR during the forecast period.
End User-Based Insights: The hemodialysis and peritoneal dialysis market, based on end user, is bifurcated into hospital-based and home-based. In 2022, the hospital-based segment held a larger share of the market. However, the home-based segment is expected to register a higher CAGR in the market during 2022–2028.
Browse Adjoining Reports: Hemodialysis Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Conventional (3 times per week), Daily (6 days a week), Nocturnal (3-6 nights per week)); Product and service (Equipment, Consumable, Drug, Service); End user (In-center dialysis, Home dialysis) and Geography
Peritoneal Dialysis Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Peritoneal Solution, Peritoneal Dialysis Catheters, Implantation Systems and Other Accessories), Type (Continuous Ambulatory Peritoneal Dialysis (CAPD) and Automated Peritoneal Dialysis (APD)), End User (Hospitals, Homecare Settings, Dialysis Centers and Others) and Geography
Kidney Disease Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product Type (Diagnosis, Treatment); End User (Hospital, Diagnostic Laboratories, Others), and Geography
Hemodialysis Catheter Market Forecast to 2028 - Covid-19 Impact and Global Analysis - By Product (Cuffed Tunneled Catheter and Non-Cuffed Tunneled Catheter, Non-Tunneled Catheter); Tip Configuration (Step-Tip Catheters, Split-Tip Catheters, Symmetric Catheters); Material (Silicone, Polyurethane); End User (Hospitals, Clinics/Dialysis Centers, Home Dialysis) and Geography
Dialysis Catheters Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Long-Term Hemodialysis Catheters, Short-Term Hemodialysis Catheters, Peritoneal Catheter); Material (Silicone, Polyurethane); End User (Hospitals, Clinics/Dialysis Centers, Home Dialysis) and Geography
Dialysis Equipment and Services Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Hemodialysis Devices, Peritoneal Devices, Continuous Renal Replacement Therapy (CRRT), and Consumables); End use (Hospitals and Clinics, Homecare Settings, Ambulatory Surgical Centers, and Others), and Geography
Medical Kidney Dialysis Machines Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Hemodialysis, Peritoneal Dialysis); End User (Hospitals, Clinics, Nursing Homes, Others) and Geography
Portable and Wearable Dialysis Devices Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product Type (Haemodialysis, Peritoneal Dialysis); End Users (Hospital, Clinic, Homes); and Geography
Urology Devices Market Forecast to 2028 - Covid-19 Impact and Global Analysis - by Product (Instruments, Consumables and Accessories); Disease (Kidney Diseases, Urological Cancer and BPH, Pelvic Organ Prolapse, Other Diseases); End User (Hospitals and Clinics, Dialysis Centers, Other End Users) and Geography
Dialyzers Market Forecast to 2028 - Covid-19 Impact and Global Analysis - by Product (High-Flux Dialyzer and Low-Flux Dialyzer), End User (In-Center Dialysis, Home Dialysis and Others), and Geography
About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Contact Us: If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi E-mail: sales@theinsightpartners.com Phone: +1-646-491-9876 Press Release: https://www.theinsightpartners.com/pr/hemodialysis-and-peritoneal-dialysis-market
What happened Shares of drugmaker Novavax (NASDAQ: NVAX) are up to the tune of 18.9% as of 2:11 p.m. ET Friday, according to data from S&P Global Market Intelligence, thanks to a confluence of events that work in the company's favor.
Whether you're looking for household goods at discounted prices or need to buy your grocery items in bulk, Costco is the go-to retailer for millions of shoppers across the U.S. But despite its ability to attract a loyal following, Costco has made a number of changes recently that haven't thrilled customers. In April, the warehouse retailer got rid of its special COVID hours for seniors, and just this month, Costco ended its mortgage program for members. Now, the retailer has a new warning for sh
Mirati is unlikely to carve out a share of the lung cancer market, analysts said Friday as MRTX stock collapsed on a testing disappointment.
Many Americans are surprised to see they have not prepared as well as they had hoped for retirement when they finally get ready to call it quits. The bad news is, you’ll probably have to make some realistic assumptions of what your retirement will look like. If you’ve lived primarily paycheck to paycheck in your working years, that may continue to feel the case in your retirement.
The stocks for companies developing cancer therapies were moving in morning trading on Friday as biotechs and researchers shared new clinical findings in advance of next week’s American Society of Clinical Oncology annual meeting. Arcellx Inc.’s (ACLX) stock jumped 11.9% after an abstract provided updated data for its CART-ddBCMA. SVB Securities analysts said in a note on Friday that they were pleased to see that the experimental therapy “continues to have a competitive efficacy signal in 24 evaluable relapsed/refractory patients.”
When looking for the best artificial intelligence stocks to buy, identify companies using AI technology to improve products or gain a strategic edge, such as Google, Microsoft and Nvidia.
Eli Lilly said Friday it will unveil new test results for its biggest cancer drug, Verzenio, in June and LLY stock broke out to a fresh high.
Billions of dollars have been poured into companies seeking early detection of cancer through common blood draws.
If there was an investing version of Paul Revere today, he might ride around proclaiming, "The stock splits are coming!" Several big companies are poised to conduct stock splits soon. Amazon (NASDAQ: AMZN) shareholders recently voted in favor of a 20-for-1 stock split scheduled for June 3, 2022. Tesla (NASDAQ: TSLA) has announced its intention to conduct a stock split this year.
Ford has been walloped. But this Wall Street firm says it has the gas to come back strong.
Tesla won't set up a manufacturing plant in India until it is first allowed to sell and service imported cars in the South Asian nation, the carmaker's chief executive Elon Musk said Friday, more than a year after an Indian state said that the electric carmaker was planning to open a plant in the southern part of the country. Responding to an individual on Twitter, who had asked for an update on Tesla's manufacturing plant in India, Musk responded, "Tesla will not put a manufacturing plant in any location where we are not allowed first to sell & service cars."
The pharma giant's drug combo is now just months away from potential U.S. approval for a type of liver cancer.
Global car production has been hampered for months because of a plethora of supply-chain and logistics issues. Friday, Toyota Motor (ticker: TM) cut its production plans again. Toyota is taking additional downtime at some plants the week of June 6.
Retirement savers are often told they’ll see a greater return in their retirement assets if they invest it – and that may be true – but it’s important to prioritize some cash in a retirement plan as well. Retirement Tip of the Week: For those close to retirement, consider keeping a portion of your retirement plan in cash – whether that be in the portfolio itself, or in a separate account. Bank and money market accounts do not generate the same type of returns as investments, though right now with volatility some investors may beg to differ.
Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Aurora, CanniMed, Daily Special, MedReleaf, and San Rafael '71. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements or cultivation facilities in more than 20 countries.
As covid-19 has become less of a threat in recent months, companies have tried different ways to get people back to the office. It’s not enough to make people like the office—or even show up to it. JPMorgan’s Jamie Dimon—previously one of the CEOs most insistent on return to the office—said in a May investor letter (pdf) that 40% of the bank’s staff would likely mix office time with home working from now on, and another 10% “in very specific roles” will likely work from home full time.
When Warren Buffett, the CEO of conglomerate Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B), buys or sells a stock, Wall Street and investors tend to pay close attention. Since taking the reins, Buffett has created close to $670 billion in value for his shareholders (which includes himself), and he's led his company's Class A shares (BRK.A) to an almost unfathomable 20.1% average annual return. To put this performance in another context, the benchmark S&P 500 has "only" gained 30,209%, including dividends paid, since Buffett took over Berkshire Hathaway.
The departure comes as the electric-truck startup is under pressure to overcome supply-chain problems that led the company to lower its production forecast for the year.
While the price of gasoline frequently steals all the headlines, the price of diesel is actually more important when it comes to the cost of living and the economy.
The highest paid CEOs in America in 2021, according to Fortune's new analysis of executive pay.